^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Melanoma |
| Drug: | Koselugo (selumetinib) (MEK inhibitor) + MK-2206 (AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK
Excerpt:
In A2058 melanoma xenograft mouse models harboring a BRAF V600E mutation and PTEN loss, but not KRAS or PIK3CA mutations, only modest antitumor activity was observed with MK-2206 and selumetinib monotherapy, whereas combination treatment again demonstrated enhanced antitumor responses (Supplementary Fig. S2; Supplementary Table S3).
DOI:
10.1158/1078-0432.CCR-14-1901
